logo-loader
viewImugene Ltd

Imugene appoints surgeon-scientist Dr Rebecca Auer to oncolytic virotherapy advisory board

Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.

Imugene Ltd - Imugene appoints surgeon-scientist Dr Rebecca Auer to oncolytic virotherapy advisory board
Dr. Auer with a patient (image courtesy - www.ottawahospital.on.ca)

Imugene Ltd (ASX:IMU) has appointed Dr Rebecca Auer to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB).

Dr Auer is an associate professor at the Department of Surgery and Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa.

She is also a surgical oncologist at The Ottawa Hospital and Tier 2 Clinical Research Chair in Perioperative Cancer Therapeutics, University of Ottawa.

As a surgeon-scientist, Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.

Perioperative cancer therapies

Dr. Auer’s translational research program focuses on understanding the promotion of metastatic disease in the perioperative period, following surgical stress.

In particular she is studying novel perioperative cancer therapies, including OVs, cancer vaccines and targeted therapies, which inhibit the formation of metastases postoperatively.

OVs are designed to both selectively kill tumour cells and deliver a potent payload, which together activate the immune system against cancer cells, with the potential to improve clinical response and survival.

Imugene M.D. & CEO Leslie Chong said: “It is a great honour for Imugene to have such a distinguished physician and scientist join our team.

“Dr. Auer has devoted her career to exploring scientific discoveries for the benefit of cancer sufferers.”

Quick facts: Imugene Ltd

Price: 0.034 AUD

ASX:IMU
Market: ASX
Market Cap: $150.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read